{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:17:54Z","timestamp":1762507074719},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.juro.2017.04.098","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T18:32:08Z","timestamp":1493922728000},"page":"1119-1123","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders"],"prefix":"10.1097","volume":"198","author":[{"given":"Johnathan A.","family":"Khusid","sequence":"first","affiliation":[{"name":"Department of Urology, State University of New York Downstate College of Medicine, Brooklyn, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey P.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Urology, State University of New York Downstate College of Medicine, Brooklyn, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin O.","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Biostatistics, Global Product Development, Pfizer Inc., New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin K.","family":"Mangan","sequence":"additional","affiliation":[{"name":"Immunology and Inflammation, Regeneron Pharmaceuticals, Inc., Tarrytown, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.04.098_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2017.04.098_bib2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.juro.2010.04.011","article-title":"The prevalence and causes of nocturia","volume":"184","author":"Bosch","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.04.098_bib3","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1464-410X.2003.04527.x","article-title":"The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA","volume":"92","author":"Coyne","year":"2003","journal-title":"BJU Int"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.04.098_bib4","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/nau.22593","article-title":"The economic impact of nocturia","volume":"33","author":"Holm-Larsen","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2017.04.098_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.juro.2010.09.108","article-title":"Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey","volume":"185","author":"Kupelian","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.04.098_bib6","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00192-006-0289-1","article-title":"Prevalence and impact of nocturia in a urogynecologic population","volume":"18","author":"Lowenstein","year":"2007","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.juro.2017.04.098_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/nau.20913","article-title":"Nocturia research: current status and future perspectives","volume":"29","author":"Van Kerrebroeck","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2017.04.098_bib8","first-page":"1396","article-title":"Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency","volume":"189","author":"Weiss","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.juro.2017.04.098_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/nau.21005","article-title":"Validation of the urinary sensation scale (USS)","volume":"30","author":"Coyne","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2017.04.098_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.juro.2017.04.098_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2009.03.080","article-title":"Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland","volume":"57","author":"Tikkinen","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.04.098_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2006.03.088","article-title":"Determining the importance of change in the overactive bladder questionnaire","volume":"176","author":"Coyne","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.04.098_bib13","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717598687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717598687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.04.098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:03:03Z","timestamp":1651208583000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.04.098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1016\/j.juro.2017.04.098"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.04.098","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.04.098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}